Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.

Spinner MA, Advani RH, Hoppe RT, Lowsky R, Muffly LS.

Blood Adv. 2018 Jul 10;2(13):1547-1550. doi: 10.1182/bloodadvances.2018021071. No abstract available.

2.

Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation.

Muffly L, Sheehan K, Armstrong R, Jensen K, Tate K, Rezvani AR, Miklos D, Arai S, Shizuru J, Johnston L, Meyer E, Weng WK, Laport GG, Negrin RS, Strober S, Lowsky R.

Blood Adv. 2018 Mar 27;2(6):681-690. doi: 10.1182/bloodadvances.2017012104.

3.

Macrochimerism and clinical transplant tolerance.

Scandling JD, Busque S, Lowsky R, Shizuru J, Shori A, Engleman E, Jensen K, Strober S.

Hum Immunol. 2018 May;79(5):266-271. doi: 10.1016/j.humimm.2018.01.002. Epub 2018 Jan 9. Review.

PMID:
29330112
4.

HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.

Spinner MA, Fernández-Viña M, Creary LE, Quinn O, Elder L, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Shizuru JA, Weng WK, Laport GG, Strober S, Lowsky R, Rezvani AR.

Blood Adv. 2017 Jul 25;1(17):1347-1357. doi: 10.1182/bloodadvances.2017007716. eCollection 2017 Jul 25.

5.

Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.

Veeraputhiran M, Yang L, Sundaram V, Arai S, Lowsky R, Miklos D, Meyer E, Muffly L, Negrin R, Rezvani A, Shizuru J, Weng WK, Johnston L.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1744-1748. doi: 10.1016/j.bbmt.2017.06.005. Epub 2017 Jun 28.

6.

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM.

Blood. 2017 Jul 13;130(2):221-228. doi: 10.1182/blood-2017-01-761346. Epub 2017 May 3.

7.

Erratum: Pregnancy Complicated by Gorham-Stout Disease and Refractory Chylothorax.

Hellyer J, Oliver-Allen H, Shafiq M, Tolani A, Druzin M, Jeng M, Rockson S, Lowsky R.

AJP Rep. 2016 Oct;6(4):e384.

8.

Pregnancy Complicated by Gorham-Stout Disease and Refractory Chylothorax.

Hellyer J, Oliver-Allen H, Shafiq M, Tolani A, Druzin M, Jeng M, Rockson S, Lowsky R.

AJP Rep. 2016 Oct;6(4):e355-e358. Erratum in: AJP Rep. 2016 Oct;6(4):e384.

9.

A Cost Analysis of Tolerance Induction for Two-Haplotype Match Kidney Transplant Recipients.

Erickson KF, Winkelmayer WC, Busque S, Lowsky R, Scandling JD, Strober S.

Am J Transplant. 2016 Jan;16(1):371-3. doi: 10.1111/ajt.13530. Epub 2015 Nov 9. No abstract available.

10.

Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.

Nakasone H, Remberger M, Tian L, Brodin P, Sahaf B, Wu F, Mattsson J, Lowsky R, Negrin R, Miklos DB, Meyer E.

Haematologica. 2015 Nov;100(11):1477-85. doi: 10.3324/haematol.2015.125294. Epub 2015 Aug 6.

11.

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.

Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, Laport GG, Miklos DB, Benjamin JE, Johnston LJ, Arai S, Weng WK, Negrin RS, Strober S, Lowsky R.

Bone Marrow Transplant. 2015 Oct;50(10):1286-92. doi: 10.1038/bmt.2015.149. Epub 2015 Jul 6.

12.

Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.

Percival MM, Medeiros BC, Tian L, Robeson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Weng WK, Negrin RS, Lowsky R.

Bone Marrow Transplant. 2015 Jul;50(7):1004-1006. doi: 10.1038/bmt.2015.62. Epub 2015 Apr 20. No abstract available.

13.

Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation.

Scandling JD, Busque S, Shizuru JA, Lowsky R, Hoppe R, Dejbakhsh-Jones S, Jensen K, Shori A, Strober JA, Lavori P, Turnbull BB, Engleman EG, Strober S.

Am J Transplant. 2015 Mar;15(3):695-704. doi: 10.1111/ajt.13091.

14.

European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Medeiros BC, Tian L, Robenson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Benjamin JE, Weng WK, Negrin RS, Lowsky R.

Blood Cancer J. 2014 May 30;4:e216. doi: 10.1038/bcj.2014.35. No abstract available.

15.

Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.

Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng WK, Negrin RS, Lowsky R.

Biol Blood Marrow Transplant. 2014 Jun;20(6):837-43. doi: 10.1016/j.bbmt.2014.02.023. Epub 2014 Mar 7.

16.

Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation.

Kohrt HE, Tian L, Li L, Alizadeh AA, Hsieh S, Tibshirani RJ, Strober S, Sarwal M, Lowsky R.

Clin Immunol. 2013 Jul;148(1):124-35. doi: 10.1016/j.clim.2013.04.013. Epub 2013 May 1.

PMID:
23685278
17.

Rare cells predict GVHD.

Strober S, Lowsky R.

Blood. 2012 May 24;119(21):4820-1. doi: 10.1182/blood-2012-04-417311. No abstract available.

18.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.

Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB.

Blood. 2012 Jun 21;119(25):6145-54. doi: 10.1182/blood-2011-12-395970. Epub 2012 May 4.

19.

Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants.

Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Sarwal M, Millan MT, Shizuru JA, Lowsky R, Engleman EG, Strober S.

Am J Transplant. 2012 May;12(5):1133-45. doi: 10.1111/j.1600-6143.2012.03992.x. Epub 2012 Mar 8.

20.

Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation.

Kohrt HE, Müller A, Baker J, Goldstein MJ, Newell E, Dutt S, Czerwinski D, Lowsky R, Strober S.

Blood. 2011 Nov 10;118(19):5319-29. doi: 10.1182/blood-2011-05-356238. Epub 2011 Aug 25.

21.

Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.

Strober S, Spitzer TR, Lowsky R, Sykes M.

Semin Immunol. 2011 Aug;23(4):273-81. doi: 10.1016/j.smim.2011.05.001. Epub 2011 Jun 25. Review.

22.

Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.

Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1679-87. doi: 10.1016/j.bbmt.2011.05.012. Epub 2011 May 25.

23.

Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.

Chen AI, Negrin RS, McMillan A, Shizuru JA, Johnston LJ, Lowsky R, Miklos DB, Arai S, Weng WK, Laport GG, Stockerl-Goldstein K.

Bone Marrow Transplant. 2012 Apr;47(4):516-21. doi: 10.1038/bmt.2011.106. Epub 2011 May 23.

24.

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation.

Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R.

Bone Marrow Transplant. 2012 Apr;47(4):581-8. doi: 10.1038/bmt.2011.104. Epub 2011 May 9.

25.

NKT cells, Treg, and their interactions in bone marrow transplantation.

Kohrt HE, Pillai AB, Lowsky R, Strober S.

Eur J Immunol. 2010 Jul;40(7):1862-9. doi: 10.1002/eji.201040394. Review.

26.

Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia.

Jones CD, Arai S, Lowsky R, Tyan DB, Zehnder JL, Miklos DB.

Br J Haematol. 2010 Sep;150(5):637-9. doi: 10.1111/j.1365-2141.2010.08252.x. Epub 2010 Jun 7. No abstract available.

27.

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY.

Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L.

Bone Marrow Transplant. 2011 Feb;46(2):192-9. doi: 10.1038/bmt.2010.114. Epub 2010 May 24.

28.

Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.

Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ.

Biol Blood Marrow Transplant. 2010 Aug;16(8):1145-54. doi: 10.1016/j.bbmt.2010.02.022. Epub 2010 Mar 1.

29.

Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update.

Kohrt H, Lowsky R.

Curr Opin Hematol. 2009 Nov;16(6):460-5. doi: 10.1097/MOH.0b013e3283319e8f. Review.

30.

Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure.

Benjamin JE, Chen GL, Cao TM, Cao PD, Wong RM, Sheehan K, Shizuru JA, Johnston LJ, Negrin RS, Lowsky R, Laport GG.

Bone Marrow Transplant. 2010 Feb;45(2):303-9. doi: 10.1038/bmt.2009.152. Epub 2009 Jul 13.

31.

Total lymphoid irradiation for graft-versus-host disease protection.

Kohrt H, Lowsky R.

Curr Opin Oncol. 2009 Jun;21 Suppl 1:S23-6. doi: 10.1097/01.cco.0000357471.68713.35. Review.

PMID:
19561409
32.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.

Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R.

Blood. 2009 Jul 30;114(5):1099-109. doi: 10.1182/blood-2009-03-211441. Epub 2009 May 7.

33.

Tolerance and chimerism after renal and hematopoietic-cell transplantation.

Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S.

N Engl J Med. 2008 Jan 24;358(4):362-8. doi: 10.1056/NEJMoa074191.

34.

RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines.

Pastural E, Takahashi N, Dong WF, Bainbridge M, Hull A, Pearson D, Huang S, Lowsky R, DeCoteau JF, Geyer CR.

Oncogene. 2007 Mar 8;26(11):1586-94. Epub 2006 Sep 4.

PMID:
16953217
35.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.

Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.

Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11.

36.

Protective conditioning for acute graft-versus-host disease.

Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S.

N Engl J Med. 2005 Sep 29;353(13):1321-31. Erratum in: N Engl J Med. 2006 Feb 23;354(8):884.

37.

Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma.

Tong J, Laport G, Lowsky R.

Bone Marrow Transplant. 2005 Oct;36(8):739-40. No abstract available.

PMID:
16086041
38.

A technique of bone marrow collection from vertebral bodies of cynomolgus macaques for transplant studies.

Flores MG, Holm B, Larson MJ, Lau MK, Si MS, Lowsky R, Rousvoal G, Grumet FC, Strober S, Hoppe R, Reitz BA, Borie DC.

J Surg Res. 2005 Apr;124(2):280-8.

PMID:
15820259
39.

CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.

Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Negrin RS, Lowsky R.

Exp Hematol. 2005 Mar;33(3):279-85.

PMID:
15730851
40.

Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose.

Cao TM, Shizuru JA, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Stuart MJ, Grumet FC, Negrin RS, Lowsky R.

Blood. 2005 Mar 15;105(6):2300-6. Epub 2004 Nov 30.

41.

Short tandem repeat analysis to monitor chimerism in macaca fascicularis.

Lau M, Vayntrub T, Grumet FC, Lowsky R, Strober S, Hoppe R, Larson M, Holm B, Reitz B, Borie D.

Am J Transplant. 2004 Sep;4(9):1543-8.

42.

Approaches to transplantation tolerance in humans.

Strober S, Lowsky RJ, Shizuru JA, Scandling JD, Millan MT.

Transplantation. 2004 Mar 27;77(6):932-6. Review.

PMID:
15077041
43.
44.

Acute Myeloblastic Leukemia: Management with High-Dose Cytosine Arabinoside, Daunorubicin and Marrow Transplantation; Malignancy; Current Clinical Practice.

Curtis JE, Hao Y, Messner HA, Lipton JH, Lowsky R, Quirt IC, Sturgeon JF, Zanke B, Keating A, Minden MD.

Hematology. 2000;5(3):177-187.

PMID:
11399613
45.
46.

Acute intestinal graft-versus-host disease in a syngeneic bone marrow transplant recipient.

Spaner D, Lowsky R, Fyles G, Lipton JH, Banerjee D, Ng CM, Wade JA, Messner HA.

Transplantation. 1998 Nov 15;66(9):1251-3.

PMID:
9825825
47.

Cloning, expression, and chromosomal localization to 11p12-13 of a human LIM/HOMEOBOX gene, hLim-1.

Dong WF, Heng HH, Lowsky R, Xu Y, DeCoteau JF, Shi XM, Tsui LC, Minden MD.

DNA Cell Biol. 1997 Jun;16(6):671-8.

PMID:
9212161
48.

Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia.

DeCoteau JF, Knaus PI, Yankelev H, Reis MD, Lowsky R, Lodish HF, Kadin ME.

Proc Natl Acad Sci U S A. 1997 May 27;94(11):5877-81.

49.
50.

Detection of donor cell derived acute myelogenous leukaemia in a patient transplanted for chronic myelogenous leukaemia using fluorescence in situ hybridization.

Lowsky R, Fyles G, Minden M, Lipton J, Meharchand J, Tejpar I, Zipursky A, Messner H.

Br J Haematol. 1996 Apr;93(1):163-5.

PMID:
8611454

Supplemental Content

Loading ...
Support Center